Andrew Siderowf

Active 2000–2025

136
Papers
27,718
Citations
84
h-index
134
i10-index

Citations

Citations per year for Andrew Siderowf1986: 1 citations1994: 2 citations2000: 1 citations2001: 1 citations2002: 2 citations2003: 17 citations2004: 29 citations2005: 33 citations2006: 39 citations2007: 58 citations2008: 74 citations2009: 107 citations2010: 135 citations2011: 228 citations2012: 232 citations2013: 313 citations2014: 289 citations2015: 314 citations2016: 285 citations2017: 338 citations2018: 328 citations2019: 1,021 citations2020: 1,102 citations2021: 1,043 citations2022: 956 citations2023: 905 citations2024: 1,535 citations2025: 909 citations2026: 53 citations1987–1993: no citations, so these years are not shown1995–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,364 citing papers, 24.4% of this breakdownUnited Kingdom: 1,251 citing papers, 9.1% of this breakdownChina: 928 citing papers, 6.7% of this breakdownGermany: 839 citing papers, 6.1% of this breakdownItaly: 709 citing papers, 5.2% of this breakdownCanada: 698 citing papers, 5.1% of this breakdownSpain: 504 citing papers, 3.7% of this breakdownFrance: 447 citing papers, 3.2% of this breakdownNetherlands: 438 citing papers, 3.2% of this breakdownSweden: 433 citing papers, 3.1% of this breakdownAustralia: 420 citing papers, 3.1% of this breakdownSwitzerland: 266 citing papers, 1.9% of this breakdown
0%24.4%Other 25.2%

Fields

  • Medicine75.6%
  • Neuroscience9.8%
  • Biochemistry, Genetics and Molecular Biology5.9%
  • Computer Science2.2%
  • Health Professions2%
  • Psychology1.9%
  • Other2.6%

Topics

  • Parkinson's Disease Mechanisms and Treatments19.1%
  • Neurological disorders and treatments9%
  • Alzheimer's disease research and treatments6.3%
  • Dementia and Cognitive Impairment Research4.9%
  • Amyotrophic Lateral Sclerosis Research2.1%
  • Voice and Speech Disorders1.8%
  • Other56.8%

Coauthors

All papers

Open in search
  1. The Parkinson Progression Marker Initiative (PPMI)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Keith A. Hawkins, Jamie L. Eberling, Deborah W. Brooks, David Russell, Laura Leary, Stewart A. Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David G. Standaert, Stephanie Guthrie, Robert A. Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi-Ann Thomas, Irene Hegeman Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly A. Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltán Mari, Melissa Gerstenhaber, David J. Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor D. Grachev, Kim P. Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, Tony W. Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor - Progress in Neurobiology 2011 cited by 1,915

  2. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2023 cited by 693

  3. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Weintraub, Yuge Xiao, Andrew Siderowf, Billy Dunn, Kenneth Marek - The Lancet Neurology 2024 cited by 563

  4. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Brain 2018 cited by 737

  5. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Clinical and Translational Neurology 2018 cited by 686

  6. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

    Authors: , , , , , , , , , , - Neurology 2006 cited by 2,464

  7. Trial of Cinpanemab in Early Parkinson’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 333

  8. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease

    Authors: , , , , , , - Neurology 2009 cited by 1,282

  9. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , A16 Study Investigators - JAMA Neurology 2020 cited by 443

  10. Neuro-QOL

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2012 cited by 780

  11. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zachary K. Sweeney, Giuseppe Astarita, Marie T. Borin, Bradley K. Wong, Harvey Wong, Hoang N. Nguyen, Kimberly Scearce‐Levie, Carole Ho, Matthew D. Troyer - Science Translational Medicine 2022 cited by 252

  12. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease

    Authors: , , , , , , , , , , , , - Movement Disorders 2021 cited by 177

  13. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Angel Figueroa, Ani Arkun, Matthew Brodsky, William G. Ondo, Christine Hunter, Joohi Jimenez‐Shahed, Alicia Palao, Janis M. Miyasaki, Julie So, James W. Tetrud, Liza Reys, Katharine Smith, Carlos Singer, Anita Blenke, David Russell, Candace Cotto, Joseph H. Friedman, Margaret C. Lannon, Lin Zhang, Edward Drasby, Rajeev Kumar, Thyagarajan Subramanian, Donna Stuppy Ford, David A. Grimes, Diane Côté, Jennifer Conway, Andrew Siderowf, Marian L. Evatt, Barbara Sommerfeld, Abraham Lieberman, Michael S. Okun, Ramon L. Rodriguez, Stacy Merritt, Camille Swartz, W. R. Wayne Martin, Pamela King, Natividad Stover, Stephanie Guthrie, Ray L. Watts, Anwar Ahmed, Hubert H. Fernandez, Adrienna Winters, Zoltán Mari, Ted M. Dawson, Becky Dunlop, Andrew Feigin, Barbara Shannon, Melissa J. Nirenberg, Mattson Ogg, Samuel A. Ellias, Cathi-Ann Thomas, Karen Frei, Iván Bódis-Wollner, Sofya Glazman, Thomas A. Mayer, Robert A. Hauser, Rajesh Pahwa, April Langhammer, Ranjit Ranawaya, Lorelei Derwent, Kapil D. Sethi, Buff Farrow, Rajan Prakash, Irene Litvan, Annette Robinson, Alok Sahay, Maureen Gartner, Vanessa K. Hinson, Samuel Markind, Melisa Pelikan and 62 more - JAMA Neurology 2014 cited by 395

  14. Questionnaire for impulsive‐compulsive disorders in Parkinson's Disease–Rating Scale

    Authors: , , , , , - Movement Disorders 2011 cited by 384

  15. Proposal for a Biologic Staging System of Parkinson’s Disease

    Authors: , , , , , , - Journal of Parkinson s Disease 2023 cited by 85

  16. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2020 cited by 201

  17. Impulse Control Disorders in Parkinson Disease

    Authors: , , , , , , , , - Archives of Neurology 2010 cited by 1,462

  18. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2018 cited by 205

  19. Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease

    Authors: , , , , , , , , , , , , , , , - Movement Disorders 2009 cited by 531

  20. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases

    Authors: , , , , , , , , , , , , , , , , , , , , - Acta Neuropathologica 2007 cited by 467

  21. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Neurology 2018 cited by 146

  22. Phosphorylated α-Synuclein in Parkinson’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2012 cited by 277

  23. Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Parkinson s Disease 2023 cited by 65

  24. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease

    Authors: , , , , , , , , , - Neurology 2010 cited by 380